Physician profile
Taylor Ryan Smith
NPI 1316444565
$25,042.01
in general payments reported to CMS, 2019-2025
39 companies · $7,170 in 2025
The $7,170 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $284 · 2021: $1,385 · 2022: $2,633 · 2023: $6,148 · 2024: $7,085 · 2025: $7,170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $8,368 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,837.63 |
| Consulting Fee | $8,367.50 |
| Education | $197.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $3,727.51 | 2022-2025 | Anzupgo, Adbry |
| Ucb, INC. | $3,629.18 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $3,446.57 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $1,823.75 | 2020-2025 | |
| Abbvie INC. | $1,434.93 | 2022-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,256.39 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $1,108.96 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $954.57 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $856.32 | 2019-2025 | Dupixent, Libtayo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $744.01 | 2019-2025 | Siliq, Duobrii, Targretin |
| Sun Pharmaceutical Industries INC. | $724.67 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Lilly USA, LLC | $658.56 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $622.97 | 2021-2025 | |
| Dermavant Sciences, INC. | $614.31 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $571.63 | 2021-2025 | Aklief, Nemluvio, Oracea |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $460.58 | 2020-2025 | Tremfya |
| Incyte Corporation | $399.65 | 2021-2024 | Opzelura |
| Epi Health, LLC | $345.66 | 2022 | |
| Amgen INC. | $314.95 | 2023-2025 | Otezla, Otezla |
| Merz North America, INC. | $237.90 | 2022-2024 | Xeomin |
| Janssen Scientific Affairs, LLC | $200.62 | 2019-2022 | |
| Organon LLC | $123.18 | 2025 | Vtama, Nexplanon |
| Botanix Sb INC | $105.78 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.03 | 2023-2025 | Spevigo |
| Organogenesis INC. | $75.56 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $72.20 | 2023-2024 | Ycanth |
| Mayne Pharma Commercial LLC | $65.30 | 2025 | |
| Dermira, INC. | $59.74 | 2019-2020 | |
| Stemline Therapeutics INC. | $57.11 | 2021 | |
| Almirall LLC | $43.37 | 2024-2025 | Seysara |
| Biofrontera INC. | $40.05 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sandoz INC. | $34.68 | 2023 | Hyrimoz |
| Paratek Pharmaceuticals, INC. | $27.10 | 2024 | Nuzyra |
| Genentech USA, INC. | $26.93 | 2023-2024 | Erivedge |
| Alkermes, INC. | $22.23 | 2024 | Vivitrol |
| Helsinn Therapeutics (U.S.), INC. | $22.08 | 2020 | |
| Celgene Corporation | $20.18 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.18 | 2024 | Simlandi |
| Nabriva Therapeutics, Plc | $13.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.